Products
-
- BBB DamageCell Death and ApoptosisNeuroinflammationNeuronal Damage and RepairOxidative StressVascular Mechanisms
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
Human CD45 ELISA Kit (AC3142)
Cat.#: ASET-1731
Specifications
Description Human CD45 ELISA Kit, a 90-minute assay kit, allows for the in vitro quantitative determination of human CD45 concentrations in serum, plasma, and other biological fluids. Size 96T Sample Type Serum, plasma or other biological fluids. Reactivity Human Unit 1 kit Packaging Kit of pre-coated 96 well microplates (12 x 8 well strips) Detection Type Colorimetric Assay Type Quantitative Sensitivity 0.09 ng/ml Precision Intra-assay CV: < 8%
Inter-assay CV: < 10%Product Range 2.5-40 ng/mL Assay Time ~90 min Storage Store the unopened kit at +4°C. Shipping Wet ice Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Assay Type Price ASET-1138 Human LUZP1 ELISA Kit (AC2549) Quantitative inquiry ASET-2030 Human p75 NGF Receptor ELISA Kit (AC3441) Quantitative inquiry ASET-2081 Human HMGN1 ELISA Kit (AC3492) Quantitative inquiry ASET-2089 Chicken CNTF ELISA Kit (AC3500) Quantitative inquiry ASET-1254 Human SHP2 ELISA Kit (AC2665) Quantitative inquiry ASET-1957 Mouse Nmur1 ELISA Kit (AC3368) Quantitative inquiry ASET-2384 Mouse LECT2 ELISA Kit (AC3795) Quantitative inquiry ASET-1792 Human PGRPS ELISA Kit (AC3203) Quantitative inquiry ASET-1085 Sheep Leptin ELISA Kit (AC2496) Quantitative inquiry ASET-1434 Rat Rabphilin 3A ELISA Kit (AC2845) Quantitative inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
0Inquiry Basket